These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2963586)

  • 61. Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment.
    Rubino CM; Bhavnani SM; Loutit JS; Lohse B; Dudley MN; Griffith DC
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311069
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose.
    Pea F; Brollo L; Viale P; Pavan F; Furlanut M
    J Antimicrob Chemother; 2003 Apr; 51(4):971-5. PubMed ID: 12654757
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pharmacokinetics of sisomicin in patients with normal and impaired renal function; its efficacy in urinary tract infection.
    Roth S; Naber K; Scheer M; Gruenwaldt G; Lange H
    Eur J Clin Pharmacol; 1976 Sep; 10(5):357-65. PubMed ID: 789084
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Population Pharmacokinetics and Pharmacodynamics of Extended-Infusion Piperacillin and Tazobactam in Critically Ill Children.
    Nichols K; Chung EK; Knoderer CA; Buenger LE; Healy DP; Dees J; Crumby AS; Kays MB
    Antimicrob Agents Chemother; 2016 Jan; 60(1):522-31. PubMed ID: 26552978
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Determination of teicoplanin in human plasma and urine by affinity and reversed-phase high-performance liquid chromatography.
    Riva E; Ferry N; Cometti A; Cuisinaud G; Gallo GG; Sassard J
    J Chromatogr; 1987 Oct; 421(1):99-110. PubMed ID: 2963015
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pharmacokinetics of piperacillin in subjects with various degrees of renal function.
    Welling PG; Craig WA; Bundtzen RW; Kwok FW; Gerber AU; Madsen PO
    Antimicrob Agents Chemother; 1983 Jun; 23(6):881-7. PubMed ID: 6225390
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Mezlocillin pharmacokinetics after single intravenous doses to patients with varying degrees of renal function.
    Frimodt-Möller N; Maigaard S; Toothaker RD; Bundtzen RW; Brodey MV; Craig WA; Welling PG; Madsen PO
    Antimicrob Agents Chemother; 1980 Apr; 17(4):599-607. PubMed ID: 6446877
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials.
    Rubino CM; Bhavnani SM; Moeck G; Bellibas SE; Ambrose PG
    Antimicrob Agents Chemother; 2015; 59(6):3365-72. PubMed ID: 25824211
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: lessons from the DALI Study.
    Roberts JA; Stove V; De Waele JJ; Sipinkoski B; McWhinney B; Ungerer JP; Akova M; Bassetti M; Dimopoulos G; Kaukonen KM; Koulenti D; Martin C; Montravers P; Rello J; Rhodes A; Starr T; Wallis SC; Lipman J;
    Int J Antimicrob Agents; 2014 May; 43(5):423-30. PubMed ID: 24630304
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Variability in Trough Total and Unbound Teicoplanin Concentrations and Achievement of Therapeutic Drug Monitoring Targets in Adult Patients with Hematological Malignancy.
    Byrne CJ; Roberts JA; McWhinney B; Fennell JP; O'Byrne P; Deasy E; Egan S; Desmond R; Enright H; Ryder SA; D'Arcy DM; McHugh J
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320714
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Teicoplanin pharmacokinetics in critically ill paediatric patients.
    Sánchez A; López-Herce J; Cueto E; Carrillo A; Moral R
    J Antimicrob Chemother; 1999 Sep; 44(3):407-9. PubMed ID: 10511412
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pharmacokinetics of meropenem in subjects with various degrees of renal impairment.
    Christensson BA; Nilsson-Ehle I; Hutchison M; Haworth SJ; Oqvist B; Norrby SR
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1532-7. PubMed ID: 1510451
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pharmacokinetics of teicoplanin in hemodialysis patients.
    Höffler D; Koeppe P; Naumann E; Lang E; Sörgel F
    Infection; 1991; 19(5):324-7. PubMed ID: 1839299
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Teicoplanin in cardiac surgery: intraoperative pharmacokinetics and concentrations in cardiac and mediastinal tissues.
    Martin C; Bourget P; Alaya M; Sertin A; Atlani C; Ennabli K; Said R
    Antimicrob Agents Chemother; 1997 May; 41(5):1150-5. PubMed ID: 9145887
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Population Pharmacokinetics of Teicoplanin in Preterm and Term Neonates: Is It Time for a New Dosing Regimen?
    Kontou A; Sarafidis K; Begou O; Gika HG; Tsiligiannis A; Ogungbenro K; Dokoumetzidis A; Agakidou E; Roilides E
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31932366
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Simplified dosing regimens of teicoplanin for patient groups stratified by renal function and weight using Monte Carlo simulation.
    Yamada T; Nonaka T; Yano T; Kubota T; Egashira N; Kawashiri T; Oishi R
    Int J Antimicrob Agents; 2012 Oct; 40(4):344-8. PubMed ID: 22818770
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
    Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
    Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Teicoplanin in the treatment of gram-positive-bacterial endocarditis.
    Martino P; Venditti M; Micozzi A; Brandimarte C; Gentile G; Santini C; Serra P
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1329-34. PubMed ID: 2529815
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pharmacokinetics of cefoperazone (2.0 g) and sulbactam (1.0 g) coadministered to subjects with normal renal function, patients with decreased renal function, and patients with end-stage renal disease on hemodialysis.
    Reitberg DP; Marble DA; Schultz RW; Whall TJ; Schentag JJ
    Antimicrob Agents Chemother; 1988 Apr; 32(4):503-9. PubMed ID: 3377461
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The pharmacokinetics and extravascular diffusion of teicoplanin in rabbits and comparative efficacy with vancomycin in an experimental endocarditis model.
    Contrepois A; Joly V; Abel L; Pangon B; Vallois JM; Carbon C
    J Antimicrob Chemother; 1988 May; 21(5):621-31. PubMed ID: 2968969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.